摘要
随着生物医学的进步,肿瘤生物治疗成为继手术、放射治疗和化学治疗之后的肿瘤治疗又一新方法。肿瘤生物治疗是通过调节机体的防御机制,调动机体自身的生物学反应而发挥抗瘤作用的一大类疗法,包括细胞因子治疗、单克隆抗体治疗、小分子化合物类治疗、细胞免疫治疗,以及基因药物治疗等。
出处
《重庆医学》
CAS
CSCD
北大核心
2012年第11期1041-1042,1046,共3页
Chongqing medicine
基金
军队临床高新技术重点资助项目(2010gxjs070)
参考文献10
-
1Jocham D,Richter A,Hoffmann L. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy:phase Ⅲ,randomised controlled trial[J].The Lancet,2004,(9409):594-599.
-
2Takayama T,Sekine T,Makuuchi M. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial[J].The Lancet,2000,(9232):802-807.
-
3Kantoff PW,Higano CS,Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].New England Journal of Medicine,2010,(05):411-422.
-
4Li H,Wang CL,Yu JP. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J].Cytotherapy,2009,(08):1076-1083.
-
5Wu CP,Jiang JT,Shi LR. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Research,2008,(6B):3997-4002.
-
6Lesterhuis WJ,de Vries IJ,Aarntzen EA. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients[J].British Journal of Cancer,2010,(09):1415-1421.
-
7Li H,Wang CL,Yu JP. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J].Cytotherapy,2009,(08):1076-1083.
-
8Zhong R,Teng J,Han B. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer[J].Cancer Immunology Immunotherapy,2011,(10):1497-1502.
-
9Chi KH,Liu SJ,Li CP. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma[J].Journal of Immunotherapy,2005,(02):129-135.doi:10.1097/01.cji.0000154248.74383.5e.
-
10Shigematsu A,Adachi A,Kiriyama N. Effects of low-dose irradiation on enhancement of immunity by dendritic cells[J].Journal of Radiation Research(Tokyo),2007,(01):51-55.
同被引文献34
-
1Jemal A, Bray F, Center MM, et al. Global Cancer Statistics [ J ]. CA Cancer J Clin,2011,61 (2) :69-90.
-
2Winter H, van den Engel NK, Rusan M, et al. Active-specific immunotherapy for non-small cell lung cancer [ J ]. J Thorac Dis, 2011,3(2) :105-114.
-
3Sovenko V, Khranovska N, Ganul V, et al. New dendritic cell immunotherapy approach : randomized phase II study in 1I B- I： A stage non-small cell lung cancer patients [ J ]. Eur J Cancer, 2009, 7(2S) :522.
-
4Perroud MW Jr, Honma HN, Barbeiro AS, et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study[J]. J Exp Clin Cancer Res,2011,30:65-72.
-
5Hirschowitz EA, Foody T, Hidalgo GE, et al. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells[ J]. Lung Cancer,2007,57(3 ) :365-372.
-
6Hirschowitz EA, Mullins A, Prajapati D ,et al. Pilot study of 1650- G: A Simplified Cellular Vaccine for Lung Cancer [ J ]. J Thorac Oncol,2011,6( 1 ) :169-173.
-
7Shi SB,Ma TH,Li CH,et a/. Effect of maintenance therapy with den- dritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer[J]. Tumori,2012,98(3) :14-319.
-
8Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage m B and IV non-small-cell lung cancer [ J ]. J Clin Oncol, 2005,23 ( 27 ) :6674-6681.
-
9Butts C, Murray RN, Smith C J, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage 1I non-small-cell lung cancer[ J ]. Clin Lung Cancer,2010,11 ( 6 ) :391-395.
-
10Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial [ J ]. The Lancet Oncology, 2011,12(12) :1125-1133.
引证文献2
-
1胡春燕,何凤,项方,卢斌.肺癌生物治疗的研究进展[J].医学综述,2013,19(23):4265-4268.
-
2马学斌,马聪,邱伟,袁红霞.CIK与DC-CIK培养特性及体外存活时间的比较[J].临床和实验医学杂志,2014,13(19):1587-1591.
-
1杨俊兰.细胞因子治疗实体瘤的现状[J].解放军医学情报,1994,8(4):178-179.
-
2黄俊祥.转移性肾癌的诊治进展[J].大家健康（学术版）,2013(3):68-69. 被引量：1
-
3高德宗,孙靖中.Fas系统与肿瘤治疗[J].国外医学（肿瘤学分册）,2005,32(5):368-371. 被引量：7
-
4彭俊杰,蔡三军.大肠癌的生物治疗进展[J].标记免疫分析与临床,2005,12(1):46-49.
-
5王薇.头颈肿瘤细胞因子治疗现状与展望[J].国外医学（耳鼻咽喉科学分册）,2000,24(1):20-23. 被引量：2
-
6王德斌.癌生物治疗进展[J].高科技与产业化,2000,6(3):15-19.
-
7肖正达,金冠球,谢宇野,林向阳,徐瑾.内镜下注细胞因子治疗晚期胃癌[J].中华消化内镜杂志,1997,14(1):38-39.
-
8郑航,李长建,李军,靳全恒,窦启锋.后腹腔镜下肾部分切除术联合过继免疫疗法应用于肾癌的疗效分析[J].湖南师范大学学报（医学版）,2016,13(4):95-97. 被引量：4
-
9杨华,王华庆.肾透明细胞癌的全身治疗现状及进展[J].国外医学（外科学分册）,2005,32(6):449-453.
-
10单婵婵,吴昌平,蒋敬庭.抗肿瘤细胞免疫治疗肿瘤患者的疗效评价[J].现代肿瘤医学,2013,21(8):1882-1884. 被引量：4
